昌吉阴道紧缩 手术做无痛人流的昌吉医院,昌吉正规医院无痛人流多少钱,昌吉包皮手术后价格,昌吉哪个医院可以修复处女膜,昌吉市哪家男科医院好,昌吉看男科医院排行榜,昌吉包茎手术大约需要多少费用

The Equifax data breach was bad for a lot of people but good for a few companies that sell identity theft protection.The hack, which Equifax announced last Thursday, exposed Social Security numbers, drivers licenses and other personal information of 143 million people. And that was just in the United States.Equifax said people in the U.K. and Canada were also affected by the data breach, but it hasn't said how many. Equifax says it has records on more than 800 million people worldwide.Demand for identity theft protection just went up. A lot.One company, LifeLock says it has gotten over 100,000 customer signups since the Equifax news broke. It said it's enrolling 10 times as many customers every hour now as a result.The Equifax breach was not the largest ever, but it was notable for the kind of information that was put at risk.LifeLock says its increase in business is greater than it was after two other big breaches -- an attack on Yahoo last year and one in 2015 against insurance giant Anthem."We've had more people sign up for LifeLock in the past three days than during the entire Yahoo or Anthem breaches," Fran Rosch, executive VP and GM of Symantec's consumer business unit, told CNN Tech on Monday.LifeLock sells identity protection like credit monitoring, black market surveillance, stolen fund reimbursements, crimes committed in your name, and fake identity monitoring. Its service costs between .99 to .99 a month.Another company that says it has seen an uptick in business is CreditKarma, which provides free credit reports and monitoring. It told CNN Tech it saw a 50% increase in signups over the weekend and a 50% increase in search traffic.CreditKarma analyzes credit profiles, suggesting product recommendations to help users save money. If you take its recommendations, it then makes a cut from the bank or lender behind the product.Equifax itself is in the fraud alert business. It has a host of products under the Equifax brand, as well as an offshoot called TrustedID. In the wake of the data breach, it is offering one year of free credit monitoring and identity theft protection with TrustedID Premier. It clarified this week that those who sign up will not be automatically renewed and charged.Of course, a year of the TrustedID service for free could be enough to convince some customers to renew and start paying."They can exploit this breach to market to consumers who never had to worry about their credit report before," said Amanda Werner, campaign manager with Americans for Financial Reform and Public Citizen.Equifax did not respond to a request for comment for this article.Experts warn that one year is not enough to cover the damage caused by the breach on consumers."Criminals will certainly try to monetize the leaked data and perform ID theft for far longer than one year after this attack," Katie Moussouris, founder of Luta Security, told CNN Tech.Bill Kowlaski, director of operations at Rehmann Corporate Investigative Services and a former FBI agent, agrees. "You're basically required ... to be extra diligent for the rest of your life."The identity theft protection market is expected to bring in .8 billion in revenue this year, according to research from IBISWorld. LifeLock has 24% of the market, with a company called Intersections owning the next biggest share, 6%. Intersections did not immediately reply to request for comment.IBISWorld said that identity theft protection offshoots owned by Experian and Equifax has a market share of less than 5%.RELATED: How to protect yourself from a data breach 3581

The Defense Department has temporarily grounded all of its 245 F-35 fighter jets for inspection of a potentially faulty engine part in the wake of last month's crash in South Carolina.Initial data from the ongoing investigation into the September 28 crash indicates a fuel tube may have been faulty. In response, all US military F-35s will be inspected as well as F-35s operated by US allies."If suspect fuel tubes are installed, the part will be removed and replaced. If known good fuel tubes are already installed, then those aircraft will be returned to flight status," the Defense Department said in a statement.Inspections are expected to be completed within the next two days, the statement said, and a defense official told CNN some aircraft have already been returned to flight status.The initial assessment is the faulty tube may be on older models of the aircraft, but all are being inspected. 911

The Cheektowaga, New York mother whose battle with breast cancer captured the hearts of many Western New Yorkers has died. Libby Gaymon, 43, passed away Tuesday. She had faced breast cancer twice in less than two years.In May, Libby's daughter Alexis asked her mom to be her date to the senior prom at McKinley High School in Buffalo. The surprise promposal was a well-coordinated effort between Alexis, her family and McKinley administrators. Alexis wanted to bring her mother because Libby didn't get to go to the prom when she was in school.On prom night, dozens of supporters of Libby packed the Gaymons' front lawn, some spilling onto the sidewalk and neighboring lawns to cheer on the mother-daughter duo.McKinley High School donated a limousine, while other community members offered free wig services, makeup application and corsage supply to make the night even more special.Most recently, Gaymon tried an experimental immunotherapy treatment at Roswell Park. Immunotherapy helps the body’s immune system attack cancer cells. It is still being studied nationwide to see if it can play a role in treating metastatic breast cancer.   Her message she shared with Buffalo-based WKBW anchor Ashley Rowe in September was clear: slow down and take time to appreciate the world around you, or else you’ll miss everything.“You’re walking down the street on the phone, either you’re on the phone or you’re texting and you’re not even seeing your surroundings," Libby said. "You’re not seeing if you walk past flowers, or if you walk past somebody smiling back at you, but you’re too busy on your phone.  You guys are letting life pass you by.”  1681

The Ebola outbreak in the Democratic Republic of Congo's North Kivu province claimed more lives as the country's Health Ministry announced on Thursday a new death in the city of Mabalako.At least 37 people have died so far in this latest outbreak, the 10th for country.Ebola cases have also been reported in the towns of Beni, Butembo, Oicha, Musienene and Mandima, according to Congo's Health Ministry.A total of 44 cases of hemorrhagic fever have been reported in the region, of which 17 are confirmed and 27 are probable, the ministry said in a statement Thursday. An additional 54 suspected cases are under investigation, the ministry said.On Tuesday, the World Health Organization confirmed that the latest cases in Congo's North Kivu province are part of the Zaire strain of the virus and that there is no link to a separate outbreak, which occurred in the western Equateur province that has since been declared over."It's good news and it's very bad news," WHO Deputy Director-General for Emergency Preparedness and Response Peter Salama told journalists in Geneva, after the new cases were first confirmed."The bad news is that this strain of Ebola carries with it the highest case-fatality-rate of any of the strains of Ebola, anywhere above 50% and higher, according to previous outbreaks," he said. "So, it's the most-deadly variant of the Ebola virus strains that we have, that's the bad news. The good news is that we do have -- although it's still an investigational product -- a safe and effective vaccine, that we were able to deploy last time around."According to WHO, this outbreak, which is in an active conflict zone, will be more complicated to contain than any that came before.Experts believe an experimental vaccine, known as rVSV-ZEBOV, made a difference in containing the earlier outbreak and vaccinations are under way in North Kivu, WHO said. A total of 3,220 doses of the vaccine are currently available in Congo and supplementary doses have been requested, WHO said.First line health workers, who had been in contact with people who were confirmed cases of Ebola, were the first to be vaccinated, WHO said."Vaccines are an important tool in the fight against Ebola," Congo's Health Minister, Oly Ilunga, said on Wednesday. "This is why it has been a priority to move them rapidly into place to begin protecting our health workers and the affected population."North Kivu province is among Congo's most populated provinces, with eight million inhabitants, according to WHO and UN. Its capital is the city of Goma. The region has been experiencing intense insecurity and a worsening humanitarian crisis, with over one million internally displaced people and a continuous outflow of refugees to neighboring countries, including Uganda, Burundi and Tanzania.WHO is working with partners in the local communities to provide information to residents on how to protect themselves from the deadly virus and answer their questions -- steps that are crucial to control an outbreak, said WHO.Congo's Health Ministry announced on August 1 that a cluster of new Ebola cases have been confirmed, just days after it declared an outbreak in Equateur province that claimed 33 lives had ended. That outbreak was the ninth recorded outbreak that Congo has seen since the virus was first discovered in 1976. 3324

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee has endorsed Pfizer’s coronavirus vaccine, in a major step toward an epic vaccination campaign that could finally conquer the outbreak. The group, in a 17-4 vote with one abstention, concluded that the shot appears safe and effective against the coronavirus in people 16 and older.The Food and Drug Administration is expected to follow the recommendation issued Thursday by its expert advisers. A final FDA decision is expected within days. The vaccine had already been authorization by officials in Canada and the UK.An emergency use authorization allows practitioners to administer a vaccine despite it not gaining full FDA approval. The EUA means that the vaccine is allowed to be used in non-clinical settings, which would allow Americans not in a trial or hospital setting to get the vaccine.Millions of shots would then ship to begin vaccinating health care workers and nursing home residents, but the Centers for Disease Control and Prevention will need to formally recommend the vaccine before health care officials can begin distributing the shots.Once it is authorized, it is expected that several million doses of the vaccine will immediately begin being distributed throughout the US to high-risk individuals. The first group of those expected to be inoculated includes health care workers and those who live or work in assisted living facilities.“The FDA recognizes that transparency and dialogue are critical for the public to have confidence in COVID-19 vaccines. I want to assure the American people that the FDA’s process and evaluation of the data for a potential COVID-19 vaccine will be as open and transparent as possible,” said FDA Commissioner Stephen M. Hahn, M.D. “The FDA has been preparing for the review of EUAs for COVID-19 vaccines for several months and stands ready to do so as soon as a EUA request is submitted. While we cannot predict how long the FDA’s review will take, the FDA will review the request as expeditiously as possible, while still doing so in a thorough and science-based manner, so that we can help make available a vaccine that the American people deserve as soon as possible.”Pfizer says that the vaccine is showing a 95% efficacy against coronavirus infection. It is one of two vaccines that could be approved by the FDA in the next few weeks. Moderna also has a vaccine candidate that is showing the efficacy of 95%.“Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally. Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”One concern over the Pfizer vaccine is possible side effects on those prone to allergic reactions. The UK’s National Health Service is advising those prone to allergic reactions to not take the Pfizer vaccine as it investigates two health care workers having apparent reactions after receiving the vaccine.Once given authorization, officials will be forced to confront two challenges: Public confidence in the vaccine and distribution. Both the Moderna and Pfizer vaccines are required to be refrigerated until use, complicating distribution methods.Also, polls are showing that a significant number of Americans are hesitant to take the vaccine. Public health experts say getting the vast majority of Americans immunized is important in order to reach herd immunity against the virus and to allow for normalcy to return to the US.In addition to a number of public health experts saying they’ll get the vaccine as a way to instill trust, former Presidents Bill Clinton, George W. Bush, and Barack Obama said they would publicly take the vaccine in order to instill faith in the shot.Widespread access to the general public is not expected until the spring. 4342